The legal landscape of pandemic innovation is shifting from a spirit of global cooperation to a theater of high-stakes litigation. In a significant ruling that underscores the strict boundaries of pharmaceutical intellectual property, the Unified Patent Court (UPC) has revoked a unitary patent for the use of remdesivir in treating COVID-19, dealing a blow to a Chinese research institute and securing a critical victory for the drug’s original developer.
The decision, handed down by the Central Milan Court, centers on a patent (EP 3854403) held by the Academy of Military Medical Sciences (AMMS) of China. The patent claimed the specific “second medical use” of remdesivir for the treatment of COVID-19. Gilead Sciences, the company that developed remdesivir, challenged the patent immediately upon its grant, arguing that the application lacked both sufficiency and the necessary “inventive step” required for patent protection.
For the broader medical community, the ruling is less about a single drug and more about the precedent it sets for how “obviousness” is defined during a global health crisis. As thousands of pandemic-era patents move through the pipeline, the UPC’s strict approach suggests that simply applying a known antiviral to a closely related new virus may not be enough to warrant new patent protections.
The Science of Inhibition: How Remdesivir Works
To understand the legal dispute, one must first understand the pharmacology of the drug. Remdesivir is a prodrug, meaning it is administered in an inactive form and metabolized into its active state once inside the host cells. Once active, it functions as a nucleotide analogue—essentially a molecular mimic of adenosine, one of the fundamental building blocks of RNA.
When the virus attempts to replicate its genetic material, it relies on an enzyme called RNA-dependent RNA polymerase to copy its genome. Remdesivir tricks the enzyme into incorporating the fake nucleotide into the growing RNA strand. This effectively jams the machinery, halting viral replication and preventing the virus from spreading further within the patient’s body.
While remdesivir became a household name during the COVID-19 pandemic, its potential was recognized long before 2020. Preclinical research had already indicated that the drug was a promising candidate for treating other coronaviruses, specifically SARS-CoV-1 (the virus responsible for the 2003 SARS outbreak) and MERS-CoV. This scientific history became the cornerstone of the UPC’s decision to revoke the AMMS patent.
The ‘Inventive Step’ and the Second Medical Use
The core of the legal battle rested on a concept known as “second medical use.” In patent law, if a drug is already known to treat one condition (the first medical use), a patent can sometimes be granted for discovering that the same drug treats a different, specific condition (the second medical use).
AMMS attempted to secure this protection by filing for the use of remdesivir specifically for SARS-CoV-2 shortly before the pandemic was officially declared and before clinical trials began in China in early 2020. However, the UPC ruled that this leap was not “inventive.”
The Court found that because the viral genome of SARS-CoV-2 had been made public early on, any “skilled person” in the field would have recognized the striking similarity between the new virus and SARS-CoV-1. Given the existing preclinical success of remdesivir against SARS-CoV-1 and MERS, the court concluded that using the drug for COVID-19 was an obvious choice rather than a breakthrough invention.
| Legal Concept | AMMS Argument | UPC Ruling |
|---|---|---|
| First Medical Use | Broad use for coronaviruses (Gilead’s prior art). | Accepted as established prior art. |
| Second Medical Use | Specific application for SARS-CoV-2. | Revoked; deemed an obvious extension. |
| Inventive Step | Novel application to a newly identified virus. | Failed; “reasonable expectation of success” existed. |
| Sufficiency | The patent provided enough detail to be used. | Dismissed as a ground for revocation. |
The End of the Pandemic Patent Truce
This ruling arrives as the pharmaceutical industry enters a more litigious era. During the height of the pandemic, several major companies publicly pledged not to enforce their patent rights to facilitate the mass production of vaccines and therapeutics. This “truce” effectively ended in May 2023, when the World Health Organization (WHO) declared the end of COVID-19 as a global health emergency.
Since then, the industry has seen a surge in infringement and invalidity proceedings. The most prominent of these are the ongoing battles between Moderna and BioNTech/Pfizer over the mRNA technology used in their respective vaccines. These disputes are not merely about royalties; they are about defining the ownership of the foundational technologies that may be used to treat future pandemics or other RNA-based diseases, such as certain cancers.
The remdesivir case highlights a broader trend: the UPC and the European Patent Office (EPO) are increasingly aligned in their strict interpretation of patent claims. The recent Enlarged Board of Appeal decision (G1/24) suggests a concerted effort to harmonize case law, ensuring that patents are not granted for “obvious” iterations of existing science, even during times of urgency.
Disclaimer: This article is for informational purposes only and does not constitute legal or medical advice. For legal guidance regarding intellectual property or medical guidance regarding COVID-19 treatment, please consult a licensed professional.
The legal saga is not yet over. Gilead Sciences is simultaneously pursuing an opposition against the same patent at the European Patent Office (EPO). While the UPC and EPO are separate entities, the current trend of uniform rulings suggests a similar outcome is likely. The next critical checkpoint will be the EPO’s decision on the opposition, which will determine if the patent remains valid in any other European jurisdictions outside the UPC’s remit.
Do you believe patent protections should be relaxed during global health emergencies, or is strict IP enforcement necessary to drive future innovation? Share your thoughts in the comments below.
